SAMSN1 and glioblastoma: However, it was not associated with the prognosis of WHO grade II, III or IV stage glioma (p>0.1).In the high- SAMSN1-expressing GBM, the median PFS of patients was 9 (95% CI 6.159 - 9.841) months, whereas in the low-SAMSN1-expressing group, the median PFS was 15 (95% CI 9.666 - 20.334) months (p = 0.002, Figure 5a).